220 related articles for article (PubMed ID: 31215209)
21. Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy.
In H; Kantor O; Sharpe SM; Baker MS; Talamonti MS; Posner MC
Ann Surg Oncol; 2016 Jun; 23(6):1956-62. PubMed ID: 26753752
[TBL] [Abstract][Full Text] [Related]
22. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
Peng L; Yang W; Zhang Z; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
[TBL] [Abstract][Full Text] [Related]
23. Postoperative adjuvant treatment for gastric cancer improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center.
Norero E; Bustos M; Herrera ME; Cerda J; González P; Ceroni M; Martínez C; Briceño E; Rojas H; Cártes R; Lopez V; Hidalgo V; Báez S; Caracci M; Viñuela E; Díaz A
Eur J Surg Oncol; 2016 Jan; 42(1):94-102. PubMed ID: 26577767
[TBL] [Abstract][Full Text] [Related]
24. Current status and future perspectives in gastric cancer management.
Roukos DH
Cancer Treat Rev; 2000 Aug; 26(4):243-55. PubMed ID: 10913380
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
[TBL] [Abstract][Full Text] [Related]
26. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
[TBL] [Abstract][Full Text] [Related]
27. Resection for gastric cancer in the community.
van de Velde CJ
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S90-3. PubMed ID: 16399441
[TBL] [Abstract][Full Text] [Related]
28. Prognosis of gastric cancer patients with node-negative metastasis following curative resection: outcomes of the survival and recurrence.
Deng J; Liang H; Sun D; Zhang R; Zhan H; Wang X
Can J Gastroenterol; 2008 Oct; 22(10):835-9. PubMed ID: 18925308
[TBL] [Abstract][Full Text] [Related]
29. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
[TBL] [Abstract][Full Text] [Related]
31. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
[TBL] [Abstract][Full Text] [Related]
32. Competing risk nomogram predicting initial loco-regional recurrence in gastric cancer patients after D2 gastrectomy.
Wang SB; Qi WX; Chen JY; Xu C; Kirova YM; Cao WG; Cai R; Cao L; Yan M; Cai G
Radiat Oncol; 2019 Jul; 14(1):128. PubMed ID: 31315683
[TBL] [Abstract][Full Text] [Related]
33. Accurate Risk Stratification of Patients with Node-Positive Gastric Cancer by Lymph Node Ratio.
Nakamura S; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
World J Surg; 2020 Dec; 44(12):4184-4192. PubMed ID: 32892273
[TBL] [Abstract][Full Text] [Related]
34. Recurrence in node-negative advanced gastric cancer: Novel findings from an in-depth pathological analysis of prognostic factors from a multicentric series.
Baiocchi GL; Molfino S; Baronchelli C; Giacopuzzi S; Marrelli D; Morgagni P; Bencivenga M; Saragoni L; Vindigni C; Portolani N; Botticini M; De Manzoni G
World J Gastroenterol; 2017 Dec; 23(45):8000-8007. PubMed ID: 29259375
[TBL] [Abstract][Full Text] [Related]
35. Staging for Remnant Gastric Cancer: The Metastatic Lymph Node Ratio vs. the UICC 7th Edition System.
Nakagawa M; Choi YY; An JY; Hong JH; Kim JW; Kim HI; Cheong JH; Hyung WJ; Choi SH; Noh SH
Ann Surg Oncol; 2016 Dec; 23(13):4322-4331. PubMed ID: 27370654
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant chemoradiation versus chemotherapy for stage III gastric cancer after surgery with curative intent.
Turanli S; Atalay C; Berberoglu U; Gulben K
J Cancer Res Ther; 2015; 11(2):369-74. PubMed ID: 26148602
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for early recurrence after radical gastrectomy followed by adjuvant chemotherapy for stage II or III gastric cancer: a multicenter, retrospective study.
Yagi S; Kumagai K; Nunobe S; Ishizuka N; Yamaguchi T; Imai Y; Tsuda M; Haruta S; Fukunaga H; Yamada T; Goto M
Jpn J Clin Oncol; 2024 Apr; 54(4):403-415. PubMed ID: 38251775
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
[TBL] [Abstract][Full Text] [Related]
39. Lymph Node Burden as a Predictive Factor for Selective Chemoradiotherapy in Patients With Locally Advanced Gastric Cancer After a D2 Dissection: A Retrospective Study.
Li Q; Li G; Palmer JD; Zhang Z
Am J Clin Oncol; 2017 Aug; 40(4):375-380. PubMed ID: 25503428
[TBL] [Abstract][Full Text] [Related]
40. Different risk factors for three major recurrence patterns of pathological stage II or III gastric cancer patients who completed adjuvant S-1 monotherapy.
Kano Y; Ohashi M; Muneoka Y; Takahari D; Chin K; Yamaguchi K; Ida S; Kumagai K; Makuuchi R; Sano T; Nunobe S
Eur J Surg Oncol; 2021 Dec; 47(12):3097-3104. PubMed ID: 33931261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
